Educational protocol hub
Selank: protocol variants and reconstitution resources
Educational hub for Selank, grouping 2 available protocol variants with links to the exact dosage and reconstitution pages.
What this hub covers
This page groups the available Selank protocol variants so readers can choose the exact vial-size guide without mixing formats.
Reconstitution workflow
Use the linked protocol pages and calculator resources to review concentration, diluent logic and unit conversions for the selected variant.
Research-only context
All information is educational and literature-focused. AllPeptides.eu does not sell peptides and does not provide medical advice.
Available protocol variants
Choose the exact guide you want to view.
Selank
Selank is a regulatory anxiolytic peptide based on tuftsin, developed in Russia. Research sources report subcutaneous administration of 300 mcg to 500 mcg, once daily (subcutaneous), increased gradually.
View protocolSelank
Research sources report subcutaneous administration of 300 mcg to 500 mcg, once daily (subcutaneous), increased gradually.
View protocolRelated research resources
Internal links that help readers and search engines understand this peptide topic cluster.
References
- Selank Anxiolytic Action — Zozulya AA, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a mechanism of its anxiolytic action. Bull Exp Biol Med. 2001;131(4):315-317.
View Source - Ershov FI et al. Vopr Virusol 2009 — Antiviral activity of immunomodulator Selank in experimental influenza infection.
View Source - Kasian A et al. Behav Neurol 2017 — Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.
View Source - Kolomin T et al. Mol Immunol 2014 — The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action.
View Source - Semenova TP et al. Neurosci Behav Physiol 2008 — Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia.
View Source - Inozemtseva LS et al. Dokl Biol Sci 2008 — Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo.
View Source - Volkova A et al. Front Pharmacol 2016 — Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.
View Source
Educational and laboratory research information only. AllPeptides.eu does not sell peptides and does not provide medical advice or human-use instructions.